Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.
Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.